8.52
0.96 (12.70%)
| Previous Close | 7.56 |
| Open | 8.00 |
| Volume | 62,042 |
| Avg. Volume (3M) | 28,008 |
| Market Cap | 89,854,848 |
| Price / Sales | 1.19 |
| Price / Book | 1.18 |
| 52 Weeks Range |
| Profit Margin | -45.59% |
| Operating Margin (TTM) | -11.41% |
| Diluted EPS (TTM) | -3.22 |
| Quarterly Revenue Growth (YOY) | 5.90% |
| Total Debt/Equity (MRQ) | 7.40% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -75.58 M |
| Levered Free Cash Flow (TTM) | -7.97 M |
| Return on Assets (TTM) | -14.39% |
| Return on Equity (TTM) | -37.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Burning Rock Biotech Limited | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.33 |
|
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 3.92% |
| % Held by Institutions | 59.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Shen Neil Nanpeng | 31 Dec 2025 | 885 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |